激活的组织内存T细胞 (CD8+CD103+CD39+) 独特地预测左侧"免疫热"结肠直肠癌的存活率
Shahd Talhouni1,2, Wakkas Fadhil3, Nigel P Mongan4,5
1Cancer Immunology Group, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, United Kingdom.
Frontiers in immunology
|May 30, 2023
概括
激活的瘤特异性T细胞 (TRM) 是比单独的CD8T细胞更好的结直肠癌存活率预测器. 左侧瘤需要TRM分析以获得准确的预后和治疗,与右侧瘤不同.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症研究 癌症研究
背景情况:
- 瘤免疫透特征,特别是CD8+T细胞,对于预测癌症患者的生存至关重要.
- 仅仅量化CD8T细胞不足以确定抗原体验.
- 通过CD103,CD39和CD8共同表达来定义的激活瘤特异性组织居民记忆CD8T细胞 (TRM),提供了更精确的测量方法.
研究的目的:
- 调查TRM细胞的丰富性和局部性是否为结直肠癌 (CRC) 患者分层提供了更高分辨率的方法.
- 在CRC生存预测中,比较TRM细胞与单独的CD8T细胞的预后值.
主要方法:
- 分析了1000例结直肠癌 (CRC) 病例的综合组织微阵列.
- 多重免疫组织化学被用来量化和确定瘤组织和相邻的正常粘膜内TRM细胞的局部化.
主要成果:
- 激活的TRM细胞是生存的独立预测因素,在所有患者中表现优于单独的CD8T细胞.
- 具有丰富激活TRM透的免疫热瘤与最佳生存结果相关.
- 在右侧和左侧CRC之间观察到显著差异:在左侧CRC中,只有激活的TRM是预后的,而在右侧CRC中,高CD8透与低TRM表明了良好的预后.
结论:
- 单独高的内CD8T细胞并不是左侧CRC的可靠生存预测指标,可能导致治疗不足.
- 在左侧CRC中评估瘤相关的TRM和CD8总T细胞,可以改善患者分层并最大限度地减少治疗不足.
- 对左侧CRC的未来免疫疗法应该旨在增强高CD8T细胞和低激活TRM的患者的免疫反应,以提高生存率.
相关概念视频
Cell-mediated Immune Responses
69.2K
Overview
69.2K
Cells of the Adaptive Immune Response
1.1K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
1.1K
T Cell Activation and Clonal Selection
845
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
845


